Amalgamated Bank Trims Stock Position in Syneos Health, Inc. (NASDAQ:SYNH)

view original post

Amalgamated Bank lowered its holdings in shares of Syneos Health, Inc. (NASDAQ:SYNHGet Rating) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,446 shares of the company’s stock after selling 1,932 shares during the quarter. Amalgamated Bank owned approximately 0.07% of Syneos Health worth $5,865,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SYNH. Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $26,000. Independence Bank of Kentucky purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $28,000. CENTRAL TRUST Co purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $44,000. Lazard Asset Management LLC purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $53,000. Finally, Lansing Street Advisors purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $59,000. Hedge funds and other institutional investors own 94.80% of the company’s stock.

Analyst Upgrades and Downgrades

SYNH has been the subject of several analyst reports. Robert W. Baird reduced their target price on shares of Syneos Health from $89.00 to $80.00 and set an “outperform” rating for the company in a report on Friday. Mizuho reduced their target price on shares of Syneos Health from $94.00 to $87.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Barclays reduced their target price on shares of Syneos Health from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, September 12th. William Blair lowered shares of Syneos Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Finally, Evercore ISI reduced their target price on shares of Syneos Health to $73.00 in a report on Tuesday, August 9th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $81.10.

Insider Activity

In other news, COO Michael Lee Brooks sold 1,002 shares of the stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $78.00, for a total transaction of $78,156.00. Following the completion of the transaction, the chief operating officer now directly owns 47,552 shares in the company, valued at approximately $3,709,056. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, General Counsel Jonathan Olefson sold 2,215 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $75.00, for a total value of $166,125.00. Following the completion of the sale, the general counsel now directly owns 25,292 shares in the company, valued at $1,896,900. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Michael Lee Brooks sold 1,002 shares of the firm’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $78.00, for a total value of $78,156.00. Following the completion of the sale, the chief operating officer now owns 47,552 shares of the company’s stock, valued at $3,709,056. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,203 shares of company stock worth $1,631,443. 0.34% of the stock is currently owned by insiders.

Syneos Health Trading Down 1.9 %

Shares of SYNH opened at $51.51 on Monday. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market cap of $5.29 billion, a P/E ratio of 19.36 and a beta of 1.74. Syneos Health, Inc. has a 1 year low of $50.74 and a 1 year high of $104.18. The company has a 50 day simple moving average of $66.90 and a two-hundred day simple moving average of $71.76.

Syneos Health (NASDAQ:SYNHGet Rating) last posted its earnings results on Tuesday, August 2nd. The company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. The firm had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.39 billion. Syneos Health had a return on equity of 14.04% and a net margin of 5.13%. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS. On average, equities analysts expect that Syneos Health, Inc. will post 4.54 earnings per share for the current fiscal year.

Syneos Health Profile

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Recommended Stories

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNHGet Rating).

Receive News & Ratings for Syneos Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Syneos Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts